Viyash Scientific Limited Allots 4,83,333 Equity Shares Under ESOP 2020 Scheme

Viyash Scientific Limited (formerly known as Sequent Scientific Limited) has completed the allotment of 4,83,333 equity shares under its Employee Stock Option Plan 2020 scheme. The company informed stock exchanges about this development through a regulatory filing dated January 29, 2026. ESOP Allotment Details The Nomination and Remuneration Committee approved the allotment through a resolution passed by circulation on January 29, 2026. The shares were issued to eligible employees under the SeQuent ESOP 2020 scheme. Parameter: Details Number of Shares Allotted: 4,83,333 equity shares Face Value: Rs. 2 per share Exercise Price: Rs. 86 per equity share Scheme: SeQuent ESOP 2020 Approval Date: January 29, 2026 Impact on Share Capital The allotment has resulted in an increase in the company's issued and paid-up equity share capital. The newly allotted shares will rank pari passu in all respects with the existing equity shares of the company. Capital Structure: Before Allotment After Allotment Paid-up Capital: Rs. 87,22,68,952 Rs. 87,32,35,618 Number of Shares: 43,61,34,476 43,66,17,809 Face Value per Share: Rs. 2 Rs. 2 Corporate Information Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is headquartered in Hyderabad, Telangana. The company trades on both BSE and NSE with scrip code 512529 and symbol VIYASH respectively. The regulatory filing was signed by Yoshita Vora, Company Secretary and Compliance Officer, confirming the completion of the ESOP allotment process. The company has requested both stock exchanges to take note of this allotment and update their records accordingly. This ESOP allotment represents part of the company's employee incentive program designed to align employee interests with shareholder value creation. Sequent Scientific Limited, now operating as Viyash Scientific Limited, has entered into a strategic partnership with Boehringer Ingelheim India Private Limited to expand its presence in India's companion animal healthcare market. The partnership, executed through Viyash Scientific's wholly owned subsidiary Alivira Animal Health Limited, focuses on distribution and promotion of Boehringer Ingelheim's companion animal products portfolio across India. Strategic Partnership Details The collaboration is designed to capture growing opportunities in India's pet healthcare market, which is experiencing significant growth driven by increased pet ownership, rising awareness of preventive care, and growing emphasis on animal well-being across the country. Partnership Aspect: Details Distribution Partner: Alivira Animal Health Limited Product Focus: Companion animal products portfolio Market Coverage: Urban and rural India Target Customers: Veterinarians and pet parents Leadership Perspectives Dr. Haribabu Bodepudi, MD & Group CEO of Viyash Scientific Limited, emphasized the significance of this partnership: "This represents an important milestone in Viyash Scientific's journey to become a key player in the companion animal segment. India offers tremendous opportunities for innovative medicines which cater to the medical needs of our pets." Dr. Vinod Gopal, Country Head, Animal Health at Boehringer Ingelheim India, highlighted the strategic alignment: "This partnership aligns with our long-term growth strategy for the animal health business in India and enables us to serve our customers with greater clarity, consistency, and care." Market Expansion Strategy The partnership leverages the complementary strengths of both organizations: Alivira's Capabilities: Extensive geographical reach and on-ground capabilities across India Boehringer Ingelheim's Portfolio: Differentiated companion animal products and robust pipeline Combined Focus: Enhanced market reach, improved access, and execution excellence Company Background Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is among the top 25 Animal Health companies globally. The company operates as an integrated pharmaceutical company with over 3,000 employees, serving customers in over 100 countries. The group maintains manufacturing, R&D, and distribution operations across India, Spain, Brazil, Turkey, and USA, with approvals from international regulatory bodies including USFDA, EUGMP, WHO, and TGA. Company Metrics: Details Global Ranking: Top 25 Animal Health companies Employee Count: Over 3,000 Market Presence: Over 100 countries Operations: India, Spain, Brazil, Turkey, USA Boehringer Ingelheim, established in India in 2003, operates as a biopharmaceutical company active in both human and animal health, with more than 53,500 employees serving over 130 markets globally. The company focuses on developing innovative therapies in areas of high unmet medical need, with key therapy areas including diabetes, cardiovascular, and respiratory conditions. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.